Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD, but the implication of bacterial virulence factors remains largely uncharacterized. Finally, AD is often associated with herpes simplex skin infections. The aim of this project is to investigate the role of staphylococcal toxins in the exacerbation and maintenance of atopic skin inflammation and in the occurrence of infectious complications such as eczema herpeticum.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atopic Dermatitis Bacterial Infections Bacterial Infections and Mycoses Bacterial Toxins Congenital, Hereditary, and Neonatal Diseases and Abnormalities Cytokines Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Gram-Positive Bacterial Infections Hypersensitivity Hypersensitivity, Immediate Immune Response Immune System Diseases Infections Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases Staphylococcal Infections Staphylococcus Aureus T Cells Subsets

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Bordeaux, Bordeaux, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with moderate AD (SCORAD between 25 and 50) or severe AD (SCORAD> 50)
Skin lesions in the forearms
Free subject, without neither guardianship, wardship nor subordination
Patient with Social Security
Informed and signed consent by the patient after clear and loyal information on the study

Exclusion criteria

Age < 18 year-old
Patients with mild AD (SCORAD < 25)
Patients without skin lesions in the forearms
Patients treated with dermocorticoid or calcineurin inhibitor for less than two weeks
Patients under systemic treatment : Methotrexate, Ciclosporin, Mycophenolate Mofetil, Azathioprine, general corticosteroids for less than 4 weeks
Patients under biological treatment : Dupilumab for less than 5 half-lives
Patient without Social Security
Pregnant and nursing women

Treatment and study plan

Skin biopsies and blood samples

Other

Two skin biopsies and 30 ml of blood will be collected.

Primary outcomes

Quantification of S. aureus colonization level and characterization of bacterial virulence profile in AD lesions.

Time frame: 2 hours (with consultation and sample)

Biological data obtained from lesional skin will be compared with those of healthy skin.

Secondary outcomes

Determination of the inflammatory profile of skin and blood during AD. Definition of the seric cytokine signature characteristic of AD. Characterization of the phenotype and function of the lymphocytic infiltrate T during AD.

Time frame: 2 hours (with consultation and sample)

Biological data obtained from lesional skin will be compared with those of healthy skin.

Sponsors and collaborators

Lead sponsor

Poitiers University Hospital

Other

Registry information

Official study title

Role of Staphylococci on Cytokine and T Cell Profiles in the Pathogenesis of Atopic Dermatitis and Eczema Herpeticum

Acronym: STADEH

Important dates

Study start: 2020
Primary completion: 2025
Study completion: 2025
First posted: Feb 18, 2020
Registry last updated: Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed